Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04FKX
|
|||
| Former ID |
DNCL002410
|
|||
| Drug Name |
D-3263
|
|||
| Synonyms |
TDBTU; 125700-69-8; N,N,N',N'-Tetramethyl-O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)uronium tetrafluoroborate; O-(3,4-Dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; MFCD00077730; AK170015; o-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-n,n,n',n'-tetramethyluroniumtetrafluoroborate; 1,1,3,3-tetramethyl-2-(4-oxobenzo[d][1,2,3]triazin-3(4h)-yl)uronium tetrafluoroborate; TDBTU; N,N,N',N'-Tetramethyl-O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)uronium tetrafluoroborate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Dendreon
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H31N3O3
|
|||
| Canonical SMILES |
CC1CCC(C(C1)C(=O)N2C3=C(C=C(C=C3)OC)N(C2=O)CCN)C(C)C
|
|||
| InChI |
1S/C21H31N3O3/c1-13(2)16-7-5-14(3)11-17(16)20(25)24-18-8-6-15(27-4)12-19(18)23(10-9-22)21(24)26/h6,8,12-14,16-17H,5,7,9-11,22H2,1-4H3/t14-,16+,17-/m1/s1
|
|||
| InChIKey |
ZGTYTFYRCIRWBL-HYVNUMGLSA-N
|
|||
| CAS Number |
CAS 947257-66-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15928782, 23130537, 24863207, 42062750, 57375470, 57649719, 75924159, 87245350, 91694285, 117656930, 118318595, 125339590, 126652203, 126664142, 136990598, 143491797, 152049580, 152243761, 160870982, 162186783, 162246152, 162278347, 163303114, 163782493, 163802232, 174526928, 184581691, 204362693, 223391286, 223656931, 223812404, 226840397, 252150885, 252265924, 252355404, 252430570, 252810060
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Long transient receptor potential channel 8 (TRPM8) | Target Info | Modulator | [2] |
| KEGG Pathway | Inflammatory mediator regulation of TRP channels | |||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00839631) Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009 Spring; 11(2): 82-107. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.